The probiotic S. boulardii has not been shown to prevent a relapse of Crohn's disease, according to a recent study in Clinical Gastroenterology and Hepatology.
A randomized, double-blind, placebo-controlled trial looked at patients with moderately severe Crohn's disease who were in remission following steroid therapies. After a one-year follow-up, 47.5 percent of patients taking the probiotic and 53.2 percent in the placebo group had relapsed.
More Articles on Gastroenterology:
Carilion Clinic Gastroenterology Adds Four Specialists, Creates Fellowship Program
FDA Supports CT Colonography Screenings for Colon Cancer Prevention
Dr. Dennis Ng Joins Ferrell-Duncan Clinic as Gastroenterologist
A randomized, double-blind, placebo-controlled trial looked at patients with moderately severe Crohn's disease who were in remission following steroid therapies. After a one-year follow-up, 47.5 percent of patients taking the probiotic and 53.2 percent in the placebo group had relapsed.
More Articles on Gastroenterology:
Carilion Clinic Gastroenterology Adds Four Specialists, Creates Fellowship Program
FDA Supports CT Colonography Screenings for Colon Cancer Prevention
Dr. Dennis Ng Joins Ferrell-Duncan Clinic as Gastroenterologist